Groundbreaking new therapies for diseases with unmet clinical need
Our mission is to develop safe and effective medicines for patients with life-threatening diseases through targeted integrin therapies
We have reached the shortlist for Start-up of the Year at the Cambridge Independent Science and Technology Awards 2023
FIND OUT MOREPrecision integrin medicines for fibrotic diseases
Our Approach
Our approach is to develop a platform of novel therapeutic agents for poorly treated medical conditions by targeting complex integrin biology, through the design, chemical synthesis, and biological and clinical evaluation of potent and selective integrin antagonists.
Pipeline
Alevin’s preclinical pipeline features small molecules that target integrin receptors and have appropriate drug-like physicochemical properties for inhaled, oral or intravenous administration.
Find out more
What are integrins?
Integrins are cell surface proteins that play complex roles in a range of physiological processes including the deposition of collagen and the build-up of scar tissue associated with fibrotic disease.
Find out more
Therapeutic applications
Our priority is an inhaled treatment for idiopathic pulmonary fibrosis, an invariably fatal lung disease. Subsequently, we will address other unmet medical needs including chronic kidney disease (CKD), acute kidney injury (AKI) and cancer.
Find out more
Alevin receives further investment from o2h Ventures alongside co-investment from the University of Nottingham’s Invention Fund
Read the Press Release